News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daxor Corporation (DXR) Announces Placement of BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy


7/12/2012 9:04:46 AM

NEW YORK, NY--(Marketwire - July 12, 2012) -

Daxor Corporation (NYSE MKT: DXR) (NYSE Amex: DXR), an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy.

North Alabama Radiopharmacy (NARP) is an independently owned nuclear pharmacy founded in 1990 to service over 25 hospitals and clinics throughout North Alabama and Southern Tennessee. They supply the materials, specialized equipment and clinical support for the diagnostic and therapy procedures utilizing radiopharmaceuticals. Their C.L.I.A. approved radiobioassay laboratory is the only one of its kind in the State of Alabama and provides many hospitals an opportunity to utilize these essential medical services.

The pharmacist and technicians at NARP and their subsidiary company, North Alabama Infusion and Compounding, are committed to providing the best possible solutions and quality care to their customers and patients. The Daxor BVA blood volume analyzer installed at NARP is the first in the State of Alabama and will help develop even better medical analyses and outcomes for patients.

The president of North Alabama Radiopharmacy, Max Akin, said, "I view this as an opportunity to improve patient outcomes for those associated with poor prognosis. I believe that this advanced testing method will become an essential service in treating heart failure and other life threatening conditions."

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:

Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES